NeoGenomics (NEO) announced it has completed its previously announced acquisition of Pathline, a CLIA/CAP/NYS-certified laboratory based in New Jersey. With the acquisition, NeoGenomics strengthens its commercial presence in the Northeast U.S. and broadens access to its comprehensive oncology test menu, expands its service capabilities, and accelerates growth in molecular and hematology-oncology testing.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics CEO Chris Smith to depart, Tony Zook to succeed
- NeoGenomics Promotes Warren Stone to President & COO
- NeoGenomics COO Melody Harris to depart, Warren Stone to succeed
- Strategic Acquisition of Pathline Boosts NeoGenomics’ Market Presence and Testing Capabilities
- NeoGenomics’ Strategic Acquisition of Pathline: A Low-Risk Investment for Market Expansion and Growth